Year All2024202320222021202020192018201720162015 Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy April 11, 2023 Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022 March 9, 2023 Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board March 1, 2023 Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations February 22, 2023 Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference February 14, 2023 Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023 February 8, 2023 Poseida Therapeutics Announces Board Change January 31, 2023 Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition December 11, 2022 Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress December 6, 2022 Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 November 10, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022 March 9, 2023
Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board March 1, 2023
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations February 22, 2023
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition December 11, 2022
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress December 6, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 November 10, 2022
